GLPG 0259

Drug Profile

GLPG 0259

Alternative Names: GLPG0259

Latest Information Update: 02 Dec 2011

Price : $50

At a glance

  • Originator Galapagos NV
  • Class Antirheumatics; Small molecules
  • Mechanism of Action MAP-kinase-activated kinase 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 09 Nov 2011 Efficacy & adverse events data from a phase II trial in Rheumatoid arthritis presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2011)
  • 15 Apr 2011 Discontinued - Phase-II for Rheumatoid arthritis in Netherlands (PO)
  • 15 Apr 2011 Discontinued - Phase-II for Rheumatoid arthritis in Poland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top